AUTHOR: LATOYA LANG
The Food and Drug Administration (FDA) has responded to MRA on our concerns regarding the confidentiality of marketing research data.
"FDA appreciates the concerns raised by MRA, and agrees with the importance of protecting the confidentiality of personal privacy information, including personally identifiable information, of those persons who participate in consumer surveys or other marketing research. Similarly, FDA understands the importance of protecting confidential commercial information, including trade secret and proprietary information."
MRA had contacted the FDA regarding the agency's sweeping demands for marketing research documents from Phillip Morris USA, Inc. to share our concerns about the need to keep respondents' personal information private and not jeopardize the research process or research trade secrets.
Read the FDA's response.
Connecticut S.B. 1103 requires the inventory of, and development of policies for, the use of artific...
A new health privacy law in Nevada, while not quite as comprehensive as a lot of the other recent st...
The Senate Judiciary Committee this summer convened a hearing “to lay the ground for legislation to...
Texas Governor Greg Abbott signed S.B. 2105 into law on June 18, 2023, establishing a ...
Rohit Chopra, director of the Consumer Financial Protection Bureau (CFPB), recently said he “will b...
The Pennsylvania Consumer Data Privacy Act (H.B. 1201) is comprehensive privacy legislation modeled ...
0 Comments